Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide

BACKGROUND: Glioblastoma (GB) is the most aggressive of all primary brain tumours and due to its highly invasive nature, surgical resection is nearly impossible. Patients typically rely on radiotherapy with concurrent temozolomide (TMZ) treatment and face a median survival of ~ 14 months. Alteration...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincent, Craig A., Nissen, Itzel, Dakhel, Soran, Hörnblad, Andreas, Remeseiro, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557167/
https://www.ncbi.nlm.nih.gov/pubmed/37803333
http://dx.doi.org/10.1186/s12885-023-11418-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557167/
https://www.ncbi.nlm.nih.gov/pubmed/37803333
http://dx.doi.org/10.1186/s12885-023-11418-9

Ejemplares similares